KalVista Pharmaceuticals (KALV) Retained Earnings (2017 - 2024)
KalVista Pharmaceuticals' Retained Earnings history spans 10 years, with the latest figure at -$580.2 million for Q4 2024.
- For Q4 2024, Retained Earnings changed N/A year-over-year to -$580.2 million; the TTM value through Dec 2024 reached -$580.2 million, changed N/A, while the annual FY2024 figure was -$469.7 million, N/A changed from the prior year.
- Retained Earnings for Q4 2024 was -$580.2 million at KalVista Pharmaceuticals, down from -$2.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$1.4 million in Q1 2020 and bottomed at -$580.2 million in Q4 2024.
- The 4-year median for Retained Earnings is -$132.2 million (2020), against an average of -$191.7 million.
- The largest annual shift saw Retained Earnings crashed 10962.23% in 2021 before it soared 99.32% in 2024.
- A 4-year view of Retained Earnings shows it stood at -$142.8 million in 2020, then dropped by 7.03% to -$152.9 million in 2021, then tumbled by 159.06% to -$396.0 million in 2023, then plummeted by 46.49% to -$580.2 million in 2024.
- Per Business Quant, the three most recent readings for KALV's Retained Earnings are -$580.2 million (Q4 2024), -$2.7 million (Q4 2024), and -$2.9 million (Q3 2024).